Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Bioanalysis considerations on the pharmacokinetic evaluation of antisense therapeutics.

Norris DA, Post N, Yu RZ, Greenlee S, Wang Y.

Bioanalysis. 2019 Oct 25. doi: 10.4155/bio-2019-0194. [Epub ahead of print] No abstract available.

PMID:
31648523
2.

A novel and translational role for autophagy in antisense oligonucleotide trafficking and activity.

Ochaba J, Powers AF, Tremble KA, Greenlee S, Post NM, Matson JE, MacLeod AR, Guo S, Aghajan M.

Nucleic Acids Res. 2019 Oct 15. pii: gkz901. doi: 10.1093/nar/gkz901. [Epub ahead of print]

PMID:
31612951
3.

Metabolism and Disposition of Volanesorsen, a 2'-O-(2 methoxyethyl) Antisense Oligonucleotide, Across Species.

Post N, Yu R, Greenlee S, Gaus H, Hurh E, Matson J, Wang Y.

Drug Metab Dispos. 2019 Oct;47(10):1164-1173. doi: 10.1124/dmd.119.087395. Epub 2019 Jul 26.

PMID:
31350288
4.

Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index.

Shen W, De Hoyos CL, Migawa MT, Vickers TA, Sun H, Low A, Bell TA 3rd, Rahdar M, Mukhopadhyay S, Hart CE, Bell M, Riney S, Murray SF, Greenlee S, Crooke RM, Liang XH, Seth PP, Crooke ST.

Nat Biotechnol. 2019 Jun;37(6):640-650. doi: 10.1038/s41587-019-0106-2. Epub 2019 Apr 29.

PMID:
31036929
5.

Characterization of the Activity and Distribution of a 2'-O-Methoxyethyl-Modified Antisense Oligonucleotide in Models of Acute and Chronic Kidney Disease.

Donner AJ, Bell TA, Greenlee S, Graham MJ, Crooke RM.

Nucleic Acid Ther. 2018 Oct;28(5):297-306. doi: 10.1089/nat.2018.0723. Epub 2018 Aug 22.

PMID:
30133341
6.

Investigation into the Mechanism(s) That Leads to Platelet Decreases in Cynomolgus Monkeys During Administration of ISIS 104838, a 2'-MOE-Modified Antisense Oligonucleotide.

Narayanan P, Shen L, Curtis BR, Bourdon MA, Nolan JP, Gupta S, Hoffmaster C, Zhou F, Christian B, Schaubhut JL, Greenlee S, Burel SA, Witztum JL, Engelhardt JA, Henry SP.

Toxicol Sci. 2018 Aug 1;164(2):613-626. doi: 10.1093/toxsci/kfy119.

PMID:
29846725
7.

Antisense oligonucleotide-mediated Dnm2 knockdown prevents and reverts myotubular myopathy in mice.

Tasfaout H, Buono S, Guo S, Kretz C, Messaddeq N, Booten S, Greenlee S, Monia BP, Cowling BS, Laporte J.

Nat Commun. 2017 Jun 7;8:15661. doi: 10.1038/ncomms15661.

8.

Inhaled ENaC antisense oligonucleotide ameliorates cystic fibrosis-like lung disease in mice.

Crosby JR, Zhao C, Jiang C, Bai D, Katz M, Greenlee S, Kawabe H, McCaleb M, Rotin D, Guo S, Monia BP.

J Cyst Fibros. 2017 Nov;16(6):671-680. doi: 10.1016/j.jcf.2017.05.003. Epub 2017 May 20.

9.

Co-Administration of an Excipient Oligonucleotide Helps Delineate Pathways of Productive and Nonproductive Uptake of Phosphorothioate Antisense Oligonucleotides in the Liver.

Donner AJ, Wancewicz EV, Murray HM, Greenlee S, Post N, Bell M, Lima WF, Swayze EE, Seth PP.

Nucleic Acid Ther. 2017 Aug;27(4):209-220. doi: 10.1089/nat.2017.0662. Epub 2017 Apr 27.

PMID:
28448194
10.

Elucidation of the Biotransformation Pathways of a Galnac3-conjugated Antisense Oligonucleotide in Rats and Monkeys.

Shemesh CS, Yu RZ, Gaus HJ, Greenlee S, Post N, Schmidt K, Migawa MT, Seth PP, Zanardi TA, Prakash TP, Swayze EE, Henry SP, Wang Y.

Mol Ther Nucleic Acids. 2016 May 10;5:e319. doi: 10.1038/mtna.2016.31.

11.

The Clinical and Economic Impacts of Skeletal-Related Events Among Medicare Enrollees With Prostate Cancer Metastatic to Bone.

McDougall JA, Bansal A, Goulart BH, McCune JS, Karnopp A, Fedorenko C, Greenlee S, Valderrama A, Sullivan SD, Ramsey SD.

Oncologist. 2016 Mar;21(3):320-6. doi: 10.1634/theoncologist.2015-0327. Epub 2016 Feb 10.

12.

Transparency, gas barrier, and moisture resistance of large-aspect-ratio vermiculite nanobrick wall thin films.

Priolo MA, Holder KM, Greenlee SM, Grunlan JC.

ACS Appl Mater Interfaces. 2012 Oct 24;4(10):5529-33. doi: 10.1021/am3014289. Epub 2012 Oct 10.

PMID:
23013618
13.

Unique O-methoxyethyl ribose-DNA chimeric oligonucleotide induces an atypical melanoma differentiation-associated gene 5-dependent induction of type I interferon response.

Burel SA, Machemer T, Ragone FL, Kato H, Cauntay P, Greenlee S, Salim A, Gaarde WA, Hung G, Peralta R, Freier SM, Henry SP.

J Pharmacol Exp Ther. 2012 Jul;342(1):150-62. doi: 10.1124/jpet.112.193789. Epub 2012 Apr 13.

PMID:
22505629
14.

When is the best time to initiate peri-operative heparin therapy in general surgery patients? A risk-benefit dilemma.

Rostambeigi N, Greenlee SM, Huebner M, Farley DR.

Am Surg. 2011 Nov;77(11):1539-45.

PMID:
22196671
15.

Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin.

Carroll JB, Warby SC, Southwell AL, Doty CN, Greenlee S, Skotte N, Hung G, Bennett CF, Freier SM, Hayden MR.

Mol Ther. 2011 Dec;19(12):2178-85. doi: 10.1038/mt.2011.201. Epub 2011 Oct 4.

16.

Long-term outcomes of laparoscopic totally extraperitoneal inguinal hernia repairs performed by supervised surgical trainees.

Zendejas B, Onkendi EO, Brahmbhatt RD, Lohse CM, Greenlee SM, Farley DR.

Am J Surg. 2011 Mar;201(3):379-83; discussion 383-4. doi: 10.1016/j.amjsurg.2010.08.019.

PMID:
21367383
17.

Contralateral metachronous inguinal hernias in adults: role for prophylaxis during the TEP repair.

Zendejas B, Onkendi EO, Brahmbhatt RD, Greenlee SM, Lohse CM, Farley DR.

Hernia. 2011 Aug;15(4):403-8. doi: 10.1007/s10029-011-0784-2. Epub 2011 Jan 23.

PMID:
21259030
18.

Patient records at Mayo Clinic: lessons learned from the first 100 patients in Dr Henry S. Plummer's dossier model.

Camp CL, Smoot RL, Kolettis TN, Groenewald CB, Greenlee SM, Farley DR.

Mayo Clin Proc. 2008 Dec;83(12):1396-9. doi: 10.1016/S0025-6196(11)60790-8. No abstract available.

PMID:
19046561
19.

Consequences of endoscopic inguinal hernioplasty with mesh on subsequent open radical prostatectomy.

Vijan SS, Wall JC, Greenlee SM, Farley DR.

Hernia. 2008 Aug;12(4):415-9. doi: 10.1007/s10029-008-0367-z. Epub 2008 Apr 1.

PMID:
18379718
20.

Postoperative hematoma following inguinal herniorrhaphy: patient characteristics leading to increased risk.

Smoot RL, Oderich GS, Taner CB, Greenlee SM, Larson DR, Cragun EB, Farley DR.

Hernia. 2008 Jun;12(3):261-5. Epub 2007 Dec 4.

PMID:
18060352
21.

Mapping, genetic isolation, and characterization of genetic loci that determine resistance to atherosclerosis in C3H mice.

Wang SS, Shi W, Wang X, Velky L, Greenlee S, Wang MT, Drake TA, Lusis AJ.

Arterioscler Thromb Vasc Biol. 2007 Dec;27(12):2671-6. Epub 2007 Oct 4.

PMID:
17916774
22.

Randomized prospective study of totally extraperitoneal inguinal hernia repair: fixation versus no fixation of mesh.

Koch CA, Greenlee SM, Larson DR, Harrington JR, Farley DR.

JSLS. 2006 Oct-Dec;10(4):457-60.

23.

Watershed-based survey designs.

Detenbeck NE, Cincotta D, Denver JM, Greenlee SK, Olsen AR, Pitchford AM.

Environ Monit Assess. 2005 Apr;103(1-3):59-81. Review.

PMID:
15861987
24.
25.

Teddy bears: an observational finding in patients with non-epileptic events.

Burneo JG, Martin R, Powell T, Greenlee S, Knowlton RC, Faught RE, Prasad A, Mendez M, Kuzniecky RI.

Neurology. 2003 Sep 9;61(5):714-5. No abstract available.

PMID:
12963774
26.

Comments on "Alcohol use and risky sex among college students".

Ridley DR, Greenlee SP.

Psychol Rep. 1995 Oct;77(2):421-2. No abstract available.

PMID:
8559867
27.

AIDS and college students: a survey of knowledge, attitudes and beliefs.

Greenlee SP, Ridley DR.

Psychol Rep. 1993 Oct;73(2):490.

PMID:
8234601

Supplemental Content

Loading ...
Support Center